M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 6.93 USD 6.45% Market Closed
Market Cap: 425.8m USD
Have any thoughts about
Monte Rosa Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one GLUE stock under the Base Case scenario is 4.03 USD. Compared to the current market price of 6.93 USD, Monte Rosa Therapeutics Inc is Overvalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLUE Relative Value
Base Case
4.03 USD
Overvaluation 42%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

28.4
P/S
P/S
Price to Sales
28.4
vs History
13
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
7.6
Forward
16.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-3.3
Industry
22.1
Forward
-4.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-5.3
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-4.5
Industry
23.4
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
11
vs Industry
49
Median 3Y
1.6
Median 5Y
1.6
Industry
2.5
More Details
12.2
EV/S
EV/S
Enterprise Value to Sales
12.2
vs History
4
vs Industry
16
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
26
Median 3Y
-1.1
Median 5Y
-1.1
Industry
4.2
Forward
-1.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
25
Median 3Y
-1
Median 5Y
-1.1
Industry
4
Forward
-1.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
26
Median 3Y
-1.5
Median 5Y
-1.7
Industry
5.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
23
Median 3Y
-1.3
Median 5Y
-1.3
Industry
3.9
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
25
vs Industry
58
Median 3Y
1.6
Median 5Y
1.8
Industry
4.5
More Details

Multiples Across Competitors

GLUE Competitors Multiples
Monte Rosa Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
425.3m USD 28.4 -3.6 -1.5 -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 039 618.2 -180 796.7 -219 544.7 -217 039.4
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852 -472.6 -514.6 -500.9
AU
CSL Ltd
ASX:CSL
133.7B AUD 5.6 31.6 19.6 24.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.1 -110 -80.2
P/S Multiple
Revenue Growth P/S to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average P/S: 3 458 324.6
28.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 039 618.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average P/E: 211.6
Negative Multiple: -3.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 796.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.6 N/A N/A
AU
CSL Ltd
ASX:CSL
31.6
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average EV/EBITDA: 16.2
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 544.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average EV/EBIT: 21.2
Negative Multiple: -1.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 039.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.9 N/A N/A
AU
CSL Ltd
ASX:CSL
24.4
54%
0.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A

See Also

Summary
GLUE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLUE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLUE stock valuation using valuation multiples.
Wall Street Estimates
GLUE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLUE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.